Abstract
Antihypertensive treatment with dihydropyridine calcium channel blockers elicits sympathetic nerve activation, which may contribute to cardiovascular events. However, recent clinical studies showed that treatment with azelnidipine, a new dihydropyridine calcium channel blocker, significantly reduced blood pressure in hypertensive patients while either maintaining or actually decreasing heart rate (HR). In this study, we examined the effects of azelnidipine and amlodipine on systemic hemodynamics and renal sympathetic nerve activity (RSNA) in anesthetized spontaneously hypertensive rats (SHR). We also examined the effects of these agents on baroreflex functions by infusing phenylephrine (30 μg/kg/min, i.v.) and sodium nitroprusside (10 μg/kg/min, i.v.) into azelnidipine- or amlodipine-treated SHR. Fifty min after administration of azelnidipine (10 μg/kg/min for 10 min, i.v.), mean arterial pressure (MAP) significantly decreased from 153±5 to 122±5 mmHg; however, HR and integrated RSNA did not change significantly (from 352±9 to 353±10 beats/min and 115±5% of baseline, respectively). Infusion of amlodipine (50 μg/kg/min for 10 min) elicited similar effects on MAP (from 152±5 to 120±4 mmHg). However, amlodipine significantly increased HR (from 351±9 to 375±11 beats/min) and integrated RSNA (165±5% of baseline). Analyses of baroreflex function curves revealed that azelnidipine-treated rats showed a smaller baroreflex function than amlodipine-treated rats (p<0.05). These data suggest that azelnidipine possesses sympathoinhibitory effects, which may be one reason why it had less pronounced effects on HR in hypertensive patients.
Similar content being viewed by others
Article PDF
References
Ogihara T, Hiwada K, Morimoto S, et al: Guidelines for treatment of hypertension in the elderly—2002 revised version. Hypertens Res 2003; 26: 1–36.
Psaty BM, Heckbert SR, Koepsell TD, et al: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–625.
Furberg CD, Psaty BM, Meyer JV : Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–1331.
Leenen FH, Ruzicka M, Huang BS : Central sympathoinhibitory effects of calcium channel blockers. Curr Hypertens Rep 2001; 3: 314–321.
Yui Y, Sumiyoshi T, Kodama K, et al, Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group : Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–191.
Iino Y, Hayashi M, Kawamura T, et al, Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators : Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21–30.
Minami J, Ishimitsu T, Kawano Y, Matsuoka H : Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol 1998; 25: 572–576.
Grassi G, Spaziani D, Seravalle G, et al: Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Hypertension 1999; 33: 671–675.
Binggeli C, Corti R, Sudano I, Luscher TF, Noll G : Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39: 892–896.
Hamada T, Watanabe M, Kaneda T, et al: Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 16: 111–118.
Tsutamoto T, Tsutsui T, Maeda K, et al: Effects of long-acting calcium channel antagonists on neurohumoral factors: comparison of nifedipine coat-core with amlodipine. J Cardiovasc Pharmacol 2003; 41: S77–S81.
Eguchi K, Kario K, Shimada K : Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002; 25: 329–333.
Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T : Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201–208.
Koike H, Kimura T, Kawasaki T, et al: Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity. Annu Rep Sankyo Res Lab 2002; 54: 1–64.
Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I : A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1999; 33: 186–192.
Fujisawa Y, Mori N, Yube K, Miyanaka H, Miyatake A, Abe Y : Role of nitric oxide in regulation of renal sympathetic nerve activity during hemorrhage in conscious rats. Am J Physiol 1999; 277: H8–H14.
Shokoji T, Nishiyama A, Fujisawa Y, et al: Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. Hypertension 2003; 41: 266–273.
Shokoji T, Fujisawa Y, Kimura S, et al: Effects of local administrations of tempol and diethyldithio-carbamic on peripheral nerve activity. Hypertension 2004; 44: 236–243.
Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T : Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol 1989; 51: 57–64.
Huang BS, Leenen FH : Sympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 42: 153–160.
Frohlich ED, McLoughlin MJ, Losem CJ, Ketelhut R, Messerli FH : Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol 1991; 68: 1346–1350.
Noll G, Wenzel RR, Shaw S, Luscher TF : Calcium antagonists and sympathetic nerve activation: are there differences between classes? J Hypertens Suppl 1998; 16: S17–S24.
Varadi G, Mori Y, Mikala G, Schwartz A : Molecular determinants of Ca2+ channel function and drug action. Trends Pharmacol Sci 1995; 16: 43–49.
Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T : Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 291: 464–473.
Furukawa T, Nukada T, Miura R, et al: Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45: 241–246.
Takahara A, Fujita S, Moki K, et al: Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells. Hypertens Res 2003; 26: 743–747.
Gao L, Wang W, Li YL, et al: Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 2004; 95: 937–944.
Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J : Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 2004; 287: H695–H703.
Shinomiya K, Mizushige K, Fukunaga M, et al: Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004; 32: 170–175.
Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T : Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43: 724–730.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shokoji, T., Fujisawa, Y., Kiyomoto, H. et al. Effects of a New Calcium Channel Blocker, Azelnidipine, on Systemic Hemodynamics and Renal Sympathetic Nerve Activity in Spontaneously Hypertensive Rats. Hypertens Res 28, 1017–1023 (2005). https://doi.org/10.1291/hypres.28.1017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.1017
Keywords
This article is cited by
-
Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis
High Blood Pressure & Cardiovascular Prevention (2023)
-
Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients
Hypertension Research (2016)
-
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity
Hypertension Research (2012)
-
Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG)
Cardiovascular Drugs and Therapy (2011)